CENTRICITY RESEARCH BLOG
How can my diet help prevent or treat NASH or NAFLD?
Non-alcoholic fatty liver disease (NAFLD) or its more serious form, non-alcoholic steatohepatitis (NASH) are common conditions caused by the storage of extra fat in the liver. Most people have no symptoms, and it doesn’t cause serious problems for them. In some cases, though, it can lead to serious liver damage.Columbus Coroner Buddy Brian’s Experience with IACT Health
COVID-19 is a virus that is continuing to impact ALL of us every single day. There is so much uncertainty surrounding this virus, and many of our front-line workers go to their jobs every day to face the unknown. This is exactly what happened to Muscogee County Coroner, Eddie “Buddy”REGN-COV2 Being Studied at IACT Health in Columbus
A new drug from Regeneron Pharmaceuticals called REGN-COV2, administered to President Donald Trump after his positive COVID-19 diagnosis, is now being studied in Columbus at the IACT Health research facility. In the medical research world, this new treatment in the fight against COVID-19 is being called an “antibody cocktail.” AccordingProfessionalization in Clinical Research and How New Investigators Can Adapt
Dr. Kingsley was interviewed by Dan Sfera, The Clinial Trials Guru, at the 2019 DIA Conference in San Diego, California. Welcome back to the Clinical Trials Guru. I’m with Dr. Kingsley at this tiny conference in San Diego called DIA. You might’ve heard about it. Dr. Kingsley has been featuredClinical Team Brings Superpowers to All-Star Challenge
Marvel Comics superheroes the Fantastic Four face off against villains with names like Annihilus, Doctor Doom, the Mole Man, and Galactus to save the day with ingenuity and commitment. A different kind of fantastic four made their debut at the ACRP 2019 annual conference in Nashville in April, representing hyperCORESites Need Technology, Infrastructure Investments To Improve Clinical Trials
Sites Need Technology, Infrastructure Investments To Improve Clinical Trials Our industry is unintentionally discouraging clinical research sites from investing in infrastructure. As a generalization, sites have the fewest resources of all the stakeholders involved in the successful execution of a clinical research trial. Most sites are very small and struggle
